Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits

Author:

Basnet Rajesh12ORCID,Khadka Sandhya3ORCID,Basnet Buddha Bahadur4ORCID,Basnet Til Bahadur5ORCID,Sapkota Sanjeep16ORCID

Affiliation:

1. Department of Biochemistry, University of Chinese Academy of Sciences, Beijing, China

2. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

3. Department of Pharmacy, Hope International College, Purbanchal University, Lalitpur, Nepal

4. Department of Medicinal Chemistry, Faculty of Science, Nepal Academy of Science and Technology, Lalitpur, Nepal

5. Department of Epidemiology, Fujian Medical University, Fuzhou, Fujian, China

6. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

Abstract

Abstract: The discovery and development of the drug/vaccine for Coronavirus Disease 2019 (COVID-19) is the process of developing a preventive vaccine or treatment drug to reduce the severity of COVID-19. Internationally, hundreds of pharmaceutical companies, biotechnology companies, university research groups, and the World Health Organization (WHO) have developed vaccines for the past few centuries. Currently, they are continuously putting effort into developing possible therapies for COVID-19 disease, which are now at various stages of the preclinical or clinical research stage. In addition, researchers are trying to accelerate the development of vaccines, antiviral drugs, and postinfection treatments. Many previously approved drug candidates are already studied to alleviate discomfort during the disease complication. In this paper, we reviewed the research progress of COVID- 19 therapeutic drugs.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3